Not Yet Recruiting OBSERVATIONAL NCT07187830

Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD (ADIPOLIVE)

Region-specific Adipose Tissues and Liver Changes Associated With Semaglutide Treatment in Chronic Kidney Disease Patients

Sponsor: Novo Nordisk Canada Inc.

Conditions Chronic Kidney Disease in Type 2 Diabetes Obesity & Overweight

Updated 3 times since 2025 Last updated: Feb 1, 2026 Started: Feb 15, 2026 Primary completion: Dec 15, 2027 Completion: Jan 15, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Chronic Kidney Disease in Type 2 Diabetes and Obesity & Overweight, this trial is actively recruiting participants. The trial is conducted by Novo Nordisk Canada Inc. and has accumulated 3 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Feb 2026 — Present [monthly]

Not Yet Recruiting
Dec 2025 — Feb 2026 [monthly]

Not Yet Recruiting
Oct 2025 — Dec 2025 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk Canada Inc.
University of Alberta

Data source: University of Alberta

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edmonton, Canada